A 27-year-old woman with poorly controlled type 1 diabetes had already lost sight in her right eye long before the accident. Then glass injured that same blind eye, surgeons repaired it, and about ten weeks later, her immune system turned on the eye she still used.
The case, described by ophthalmologists led by the King Khaled Eye Specialist Hospital and Research Center in Riyadh and published in BMC Ophthalmology, documents a rare inflammatory disease colliding with advanced diabetic eye disease in a woman who could not afford to lose either.
A Damaged Eye Blind for Years Still Set Off the Attack
Sympathetic ophthalmia is a bilateral granulomatous inflammation that follows penetrating injury or surgery to one eye. Ophthalmologists call the injured eye the exciting eye and the second one the sympathizing eye. The prevailing explanation is a T-cell response against proteins from the uvea, the pigmented middle layer, that the immune system normally never encounters.
The authors cite reported rates of roughly 0.1% after intraocular surgery and 0.2% to 0.5% after penetrating trauma, with onset ranging from days to decades afterward. The shortest latency on record is five days.
What makes this patient's case instructive is the state of the injured eye. Her right eye had documented no light perception before the glass injury ever happened, and it later became phthisical, meaning shrunken and non-functional. It could not see, and it never would again. The treating team still identified the penetrating injury and its surgical repair as the inciting events, because exposure of uveal antigens can trigger the response even from a severely damaged eye. A blind eye is not an inert one.
Her left eye, previously 20/20 and now her only functional eye, dropped to 20/100. Examination found keratic precipitates, inflammatory cells in the anterior chamber, a hyperemic optic disc, and an exudative retinal detachment overlying active proliferative diabetic retinopathy with new vessel growth despite prior laser treatment.
The timeline matters here because pregnancy enters this story twice, and neither entry is the beginning. She was not pregnant when the inflammation began. Her obstetric history included a medical termination at 18 weeks and six days, two weeks before she presented, for fetal congenital anomalies. A second pregnancy came later.
Steroids Were the Obvious Treatment and the Riskiest One for Her
High-dose intravenous corticosteroids are the standard opening move for sympathetic ophthalmia, and she received methylprednisolone at 1 gram daily for five days. In someone with poorly controlled type 1 diabetes of 15 years' duration, this is also a direct route to dangerous blood sugar elevation. The authors point to published work showing that patients with inflammatory eye disease on systemic steroids face a meaningful risk of hyperglycemia requiring medical treatment.
The team introduced adalimumab, a TNF inhibitor with established evidence in noninfectious uveitis, early as a steroid-sparing agent specifically to limit cumulative steroid exposure. She started with an 80 mg loading dose, then 40 mg a week later, then 40 mg every two weeks, while oral prednisolone was tapered from 50 mg a day.
Calming the Inflammation Also Quieted Her Diabetic Eye Disease
The most surprising observation came next, and it runs against the usual mental model of diabetic retinopathy as a purely microvascular problem.
After systemic control of the inflammation, her abnormal new blood vessels partially regressed without any additional laser treatment and without a single injection of anti-VEGF medication. Laser treatment was performed two months later, and her vision improved to 20/25.
The authors read this as evidence that severe intraocular inflammation can act as a second hit on an already oxygen-starved diabetic retina, worsening ischemia and driving neovascular activity, and that quieting the inflammation can indirectly ease the diabetic component. They point to supporting evidence, including a cohort study in Ophthalmology Science finding that eyes with both proliferative diabetic retinopathy and uveitis had higher rates of fibrovascular proliferation, neovascular glaucoma, and tractional detachment than eyes with diabetic retinopathy alone.
Pregnancy Reopened the Problem and Forced a Surgical Delay
A second pregnancy complicated the course. She developed recurrent vitreous hemorrhages and progressive tractional membranes threatening the macula.
Pregnancy is an independent driver of short-term retinopathy progression. A systematic review in JAMA Ophthalmology documented worsening of diabetic retinopathy during gestation in women with pre-existing diabetes. The authors describe her situation as involving converging risk factors rather than a single mechanism: poor glycemic control, active inflammation, and pregnancy.
Adalimumab was continued after multidisciplinary counseling, a decision the team individualized because she had one working eye and a real risk of a sight-threatening flare. Anti-VEGF injections were avoided during the pregnancy itself over theoretical concerns about placental angiogenesis, with laser preferred instead. Surgery was deferred to the postpartum period, when she underwent pars plana vitrectomy with membrane peeling, endolaser, and gas tamponade. At last follow-up, her vision was 20/40 with a flat, attached retina and quiet inflammation, with cataract limiting further gain.
This is one patient, and it establishes no treatment rule. The practical point is narrower: an injury to a blind eye is still an eye emergency worth following up on, and new redness, light sensitivity, or blurring in the other eye after any eye trauma or surgery warrants prompt evaluation. Anyone with diabetes and an eye injury should discuss monitoring with an ophthalmologist rather than drawing conclusions from a single report.
Key Questions Answered
What is sympathetic ophthalmia? A rare immune-mediated inflammation of both eyes that follows penetrating injury or surgery to one of them. The uninjured eye is the one that loses vision.
How common is it? The report cites roughly 0.1% after intraocular surgery and 0.2% to 0.5% after penetrating trauma. Onset has been reported anywhere from five days to decades after the injury.
Why did a blind eye trigger it? Because the trigger is the exposure of proteins from the eye's pigmented middle layer to the immune system. That can happen even in an eye that no longer sees and later shrinks.
Why was treatment complicated here? High-dose steroids are the standard therapy but can severely destabilize blood sugar in type 1 diabetes. The team added adalimumab early to limit steroid exposure.
What was the unexpected finding? Controlling the inflammation alone caused partial regression of her diabetic new vessel growth, without additional laser or anti-VEGF injections.
What should someone do after an eye injury? Follow up as directed and seek prompt evaluation if the other eye develops redness, light sensitivity, floaters, or blurred vision. This is a single case and not a basis for changing anyone's treatment.
